+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cell Line Development - Global Strategic Business Report

  • PDF Icon

    Report

  • 193 Pages
  • April 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5027993
The global market for Cell Line Development is estimated at US$8.1 Billion in 2023 and is projected to reach US$14.7 Billion by 2030, growing at a CAGR of 7.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Cell Line Development Reagents & Media segment, which is expected to reach US$8.7 Billion by 2030 with a CAGR of 8.3%. The Cell Line Development Equipment segment is also set to grow at 7.2% CAGR over the next 8 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $2.5 Billion in 2023, and China, forecasted to grow at an impressive 7.1% CAGR to reach $2.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Cell Line Development Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cell Line Development Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Cell Line Development Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Abzena PLC, American Type Culture Collection (ATCC), Apath LLC, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 44 Featured):

  • Abzena PLC
  • American Type Culture Collection (ATCC)
  • Apath LLC
  • Bioceros
  • Catalent, Inc.
  • CELLforCURE
  • Cobra Biologics
  • Corning, Inc.
  • Cyagen US Inc.
  • Cytovance Biologics
  • Epistem Holdings PLC
  • EuBiologics Co., Ltd.
  • GE Healthcare
  • GVK Biosciences Private Limited
  • Hitachi Chemical Advanced Therapeutics Solutions, LLC
  • Lonza Group Ltd.
  • MilliporeSigma
  • NAEJA-RGM Pharmaceuticals, Inc.
  • Paragon Bioservices, Inc.
  • Patheon, Inc.
  • Promocell GmbH
  • Samsung BioLogics
  • Sartorius AG
  • Selexis SA
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Cell Line Development - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Bioproduction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 2: World 7-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 3: World Recent Past, Current & Future Analysis for Tissue Engineering & Regenerative medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 4: World 7-Year Perspective for Tissue Engineering & Regenerative medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Toxicity Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World 7-Year Perspective for Toxicity Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 8: World 7-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 9: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 10: World 7-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World 7-Year Perspective for Mammalian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Non-Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 14: World 7-Year Perspective for Non-Mammalian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 15: World Recent Past, Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 16: World 7-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Hybridomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World 7-Year Perspective for Hybridomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Continuous Cell Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 20: World 7-Year Perspective for Continuous Cell Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 21: World Recent Past, Current & Future Analysis for Primary Cell Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 22: World 7-Year Perspective for Primary Cell Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Reagents & Media by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 24: World 7-Year Perspective for Reagents & Media by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 26: World 7-Year Perspective for Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 27: World Recent Past, Current & Future Analysis for Accessories & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 28: World 7-Year Perspective for Accessories & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 29: World Cell Line Development Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 30: World Recent Past, Current & Future Analysis for Cell Line Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 31: World 7-Year Perspective for Cell Line Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 32: USA Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: USA 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
  • Table 34: USA Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 35: USA 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
  • Table 36: USA Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 37: USA 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • Table 38: USA Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: USA 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
CANADA
  • Table 40: Canada Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 41: Canada 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
  • Table 42: Canada Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 43: Canada 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
  • Table 44: Canada Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Canada 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • Table 46: Canada Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 47: Canada 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
JAPAN
  • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 48: Japan Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 49: Japan 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
  • Table 50: Japan Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: Japan 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
  • Table 52: Japan Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 53: Japan 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • Table 54: Japan Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 55: Japan 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
CHINA
  • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 56: China Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: China 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
  • Table 58: China Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 59: China 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
  • Table 60: China Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 61: China 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • Table 62: China Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: China 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
EUROPE
  • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 64: Europe Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 65: Europe 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
  • Table 66: Europe Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 67: Europe 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
  • Table 68: Europe Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 69: Europe 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • Table 70: Europe Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 71: Europe 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
  • Table 72: Europe Recent Past, Current & Future Analysis for Cell Line Development by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 73: Europe 7-Year Perspective for Cell Line Development by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
FRANCE
  • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 74: France Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 75: France 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
  • Table 76: France Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 77: France 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
  • Table 78: France Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 79: France 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • Table 80: France Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 81: France 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
GERMANY
  • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 82: Germany Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 83: Germany 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
  • Table 84: Germany Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 85: Germany 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
  • Table 86: Germany Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 87: Germany 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • Table 88: Germany Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 89: Germany 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
ITALY
  • Table 90: Italy Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 91: Italy 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
  • Table 92: Italy Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 93: Italy 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
  • Table 94: Italy Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 95: Italy 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • Table 96: Italy Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 97: Italy 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
UNITED KINGDOM
  • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 98: UK Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 99: UK 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
  • Table 100: UK Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 101: UK 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
  • Table 102: UK Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 103: UK 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • Table 104: UK Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 105: UK 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
REST OF EUROPE
  • Table 106: Rest of Europe Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 107: Rest of Europe 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
  • Table 108: Rest of Europe Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 109: Rest of Europe 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
  • Table 110: Rest of Europe Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 111: Rest of Europe 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • Table 112: Rest of Europe Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 113: Rest of Europe 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
ASIA-PACIFIC
  • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 114: Asia-Pacific Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 115: Asia-Pacific 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
  • Table 116: Asia-Pacific Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 117: Asia-Pacific 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
  • Table 118: Asia-Pacific Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 119: Asia-Pacific 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • Table 120: Asia-Pacific Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 121: Asia-Pacific 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abzena PLC
  • American Type Culture Collection (ATCC)
  • Apath LLC
  • Bioceros
  • Catalent, Inc.
  • CELLforCURE
  • Cobra Biologics
  • Corning, Inc.
  • Cyagen US Inc.
  • Cytovance Biologics
  • Epistem Holdings PLC
  • EuBiologics Co., Ltd.
  • GE Healthcare
  • GVK Biosciences Private Limited
  • Hitachi Chemical Advanced Therapeutics Solutions, LLC
  • Lonza Group Ltd.
  • MilliporeSigma
  • NAEJA-RGM Pharmaceuticals, Inc.
  • Paragon Bioservices, Inc.
  • Patheon, Inc.
  • Promocell GmbH
  • Samsung BioLogics
  • Sartorius AG
  • Selexis SA
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec

Table Information